Document is current

Article History

Received: 17 September 2021

Accepted: 14 January 2022

First Online: 3 February 2022

Declarations

:

: All procedures performed were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments. The Institutional Review Boards at each participating center reviewed and approved the study protocol.

: Written informed consent was obtained from all individual participants included in the study.

: Written informed consent was obtained from all individual participants included in the study.

: Not applicable.

: All procedures performed were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments. The Institutional Review Boards at each participating center reviewed and approved the study protocol.

: JB serves on the advisory board or is a consultant for FivePrime, Clovis, Ipsen, Bayer, Mirati, Puma, and Insmed. AWT serves on the advisory board for ADAGENE, Inc, ARO BIOTHERAPEUTICS, BIOINVENT, Boeringer Ingelheim International GmbH, Deka Biosciences, Eleven Bio, ELUCIDA, EMD SERONO/ MERCK KGaA, IMMUNOME, NBE THERAPEUTICS, Pelican, Pieris Pharma, PYXIS Oncology, Vincerx, and Zymeworks Biopharmaceuticals, Inc, and is a consultant for ABBVIE, Inc., AGENUS, Inc, ASANA BIOSCIENCES, ASCENTAGE, AxImmune, Bayer, GILDE HEALTHCARE PARTNERS, HBM PARTNERS, Immunomet Therapeutics, Inc., Karma Oncology B.V., Mekanistic Therapeutics, Menarini Ricerche, Mersana, NANOBIOTIX, Partner Therapetucs, Pfizer, PIERRE FABRE, RYVU THERAPEUTICS, Seattle Genetics, SOTIO Biotechnology Co., Spirea Limited Inc., Transcenta Therapeutics Inc., and Trillium Therapetics Inc.; all free for consulting and advisory boards memberships for AWT are paid to his institution of which he is president and co-founder. CD, IDH, and MWP were employees at Symphogen when this study was performed. JGW does not have any relevant disclosures. UHH and NJOS are employees at Symphogen but do not have any financial, economic, intellectual rights or other conflict of interest with the content in this paper. DW is a consultant/contractor for Symphogen A/S, Tessa Therapeutics, Iksuda Therapeutics, and Bristol Myers Squibb. PIN is a consultant/contractor for Symphogen A/S, Tessa Therapeutics, and Iksuda Therapeutics. AP serves as a consultant of advisor for Seattle Genetics, Silverback Therapeutics, Bayer, Daiichi Sankyo, Inc., Novartis, Gilead Sciences, HalioDx, Merck, and Shenzhen IONOVA Life Sciences Co., Ltd. On behalf of their institutions, JB, AWT, and AP received research funding from Symphogen.